FLT3 Inhibitor-Associated Neutrophilic Dermatoses

JAMA Dermatol. 2016 Apr;152(4):480-2. doi: 10.1001/jamadermatol.2015.6121.

Authors

Nisha Varadarajan¹, Andrea Boni², David E Elder³, Adam Bagg³, Robert Micheletti⁴, Alexander E Perl⁵, Misha Rosenbach⁴

Affiliations

¹ Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia.
² Department of Pathology, The University of Arizona College of Medicine, Tucson.
³ Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia.
⁴ Department of Dermatology and Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia.
⁵ Division of Hematology and Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia.

PMID: 26886840
DOI: 10.1001/jamadermatol.2015.6121

No abstract available

Publication types

Case Reports
Research Support, N.I.H., Extramural

MeSH terms

Adult
Aged
Antineoplastic Agents / administration & dosage
Antineoplastic Agents / adverse effects*
Antineoplastic Agents / pharmacology
Female
Humans
Leukemia, Myeloid, Acute / drug therapy*
Leukemia, Myeloid, Acute / genetics
Male
Middle Aged
Neutrophil Infiltration / drug effects
Protein Kinase Inhibitors / administration & dosage
Protein Kinase Inhibitors / adverse effects*
Protein Kinase Inhibitors / pharmacology
Skin Diseases / chemically induced*
fms-Like Tyrosine Kinase 3 / antagonists & inhibitors*
fms-Like Tyrosine Kinase 3 / genetics

Substances

Antineoplastic Agents
Protein Kinase Inhibitors
fms-Like Tyrosine Kinase 3

Grants and funding

1K23CA141054/CA/NCI NIH HHS/United States